肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

2022 一般共识声明：顺铂肾毒性的预防

2022-02-08 国外肿瘤科相关专家小组（统称） Int J Prev Med

顺铂肾毒性

多数实体瘤患者在临床上接受顺铂（CP）化疗，其最常见的副作用是肾毒性。本文主要针对顺铂肾毒性的预防提供一般性共识指导，以限制药物引起的肾毒性。

中文标题：

2022 一般共识声明：顺铂肾毒性的预防

英文标题：

The Prevention of Cisplatin-Induced Nephrotoxicity: A General Consensus Statement

发布机构：

国外肿瘤科相关专家小组（统称）

发布日期：

2022-02-08

简要介绍：

多数实体瘤患者在临床上接受顺铂（CP）化疗，其最常见的副作用是肾毒性。本文主要针对顺铂肾毒性的预防提供一般性共识指导，以限制药物引起的肾毒性。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 一般共识声明：顺铂肾毒性的预防.pdf)] GetToolGuiderByIdResponse(projectId=1, id=88b421c002a0e576, title=2022 一般共识声明：顺铂肾毒性的预防, enTitle=The Prevention of Cisplatin-Induced Nephrotoxicity: A General Consensus Statement, guiderFrom=Int J Prev Med, authorId=0, author=, summary=多数实体瘤患者在临床上接受顺铂（CP）化疗，其最常见的副作用是肾毒性。本文主要针对顺铂肾毒性的预防提供一般性共识指导，以限制药物引起的肾毒性。, cover=https://img.medsci.cn/20220411/1649664779960_1608702.png, journalId=0, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Tue Feb 08 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">多数实体瘤患者在临床上接受顺铂（CP）化疗，其最常见的副作用是肾毒性。本文主要针对顺铂肾毒性的预防提供一般性共识指导，以限制药物引起的肾毒性。</span></p>, tagList=[TagDto(tagId=436546, tagName=顺铂肾毒性)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=14, categoryName=肾内科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=13227, appHits=97, showAppHits=0, pcHits=399, showPcHits=13130, likes=1, shares=15, comments=3, approvalStatus=1, publishedTime=Tue Apr 12 15:03:00 CST 2022, publishedTimeString=2022-02-08, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Mon Apr 11 16:14:34 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Fri Jan 05 16:19:36 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 一般共识声明：顺铂肾毒性的预防.pdf)])
2022 一般共识声明：顺铂肾毒性的预防.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1221800, encodeId=290c1221800ac, content=真的有这个, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15b46559670, createdName=ms8000001688280701, createdTime=Mon May 23 17:00:00 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218584, encodeId=61c6121858478, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10658139247, createdName=ms9000000231852747, createdTime=Tue May 10 22:14:05 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210574, encodeId=654a12105e425, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Tue Apr 12 15:26:20 CST 2022, time=2022-04-12, status=1, ipAttribution=)]
    2022-05-23 ms8000001688280701

    真的有这个

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1221800, encodeId=290c1221800ac, content=真的有这个, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15b46559670, createdName=ms8000001688280701, createdTime=Mon May 23 17:00:00 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218584, encodeId=61c6121858478, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10658139247, createdName=ms9000000231852747, createdTime=Tue May 10 22:14:05 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210574, encodeId=654a12105e425, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Tue Apr 12 15:26:20 CST 2022, time=2022-04-12, status=1, ipAttribution=)]
    2022-05-10 ms9000000231852747

    感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1221800, encodeId=290c1221800ac, content=真的有这个, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15b46559670, createdName=ms8000001688280701, createdTime=Mon May 23 17:00:00 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218584, encodeId=61c6121858478, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10658139247, createdName=ms9000000231852747, createdTime=Tue May 10 22:14:05 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210574, encodeId=654a12105e425, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Tue Apr 12 15:26:20 CST 2022, time=2022-04-12, status=1, ipAttribution=)]
    2022-04-12 jing0309

    感谢分享

    0